^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CWP291

    i
    Other names: CWP291, CWP-232291, CWP232291, CWP 232291, CWP 291, CWP-291
    Associations

    News

    Trials
    Company:
    JW Pharma
    Drug class:
    Wnt signalling pathway inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. (PubMed, Front Oncol)
    Noticeably, CWP232291 could also s suppress the growth of cisplatin-resistant cell lines and ovarian cancer patient-derived organoids. Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    cisplatin • CWP291
    over2years
    Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. (PubMed, Cancer Med)
    Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway.
    Journal
    |
    BCL2L1 (BCL2-like 1) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation
    |
    CWP291
    over4years
    Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. (PubMed, Blood Adv)
    Future studies will explore CWP291, with a mechanism of action aimed at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. This trial was registered at www.clinicaltrials.gov as #NCT01398462.
    Clinical • P1 data • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    CWP291